To the Editor
The signal transducer and activator of transcription 5B (STAT5B), downstream of IL-15 signaling and Janus kinase (JAK)1, and 3-mediated activation, is a master regulator of development, survival, and function of innate and innate-like lymphocytes (including natural killer (NK) and NKT cells) [1,2,3]. Gain-of-function mutations in the SH2 domain of human STAT5B, especially STAT5BN642H, are associated with aggressive forms of CD56+ T cell (NKT) and NK cell lymphomas/leukemias [4,5,6]. We described a mouse model expressing human (h)STAT5BN642H under the Vav-1 promoter, which develops severe CD8+ T cell neoplasia [7]. Here, we explore the ability of hSTAT5BN642H to serve as an oncogenic driver in innate lymphocyte neoplasms.
We found an increase in absolute NK cell numbers in the spleen of T cell-diseased hSTAT5BN642H transgenic compared to wild-type (WT) mice (Fig. 1a), despite the relative decrease of the proportion of NK cells among splenic lymphocytes (Fig. S1A), while nonmutant hSTAT5B control mice showed intermediate NK cell numbers (Fig. 1a, Fig. S1A). No significant differences in NK cell numbers were observed in the bone marrow (BM) between genotypes (Fig. S1B). In addition, both hSTAT5B and hSTAT5BN642H mice showed a similar increase in the proportion of mature NK cells (CD27−CD11b+ and KLRG1+) in the spleen (Fig. S1C, D). These findings suggest that the enforced expression of nonmutant hSTAT5B is sufficient to boost NK cell maturation, which is not further enhanced by introducing the activating hSTAT5B mutation. We hypothesized that any phenotypic alterations affecting innate lymphocytes might be masked by the hSTAT5BN642H-driven aggressive CD8+ T cell disease established in hSTAT5BN642H mice at the age of 6–8 weeks [7]. To explore the potential of hSTAT5BN642H to promote NK cell expansion in vivo, we transplanted CD3-depleted BM from hSTAT5BN642H or hSTAT5B mice in immune-deficient Rag2−/−γc−/− recipient mice. Using this approach, we observed an enhanced expansion of NK cells in the blood of hSTAT5BN642H compared to hSTAT5B-transplanted recipients over a time course of 4 weeks (Fig. 1b). Long-term analysis of NK cells in hSTAT5BN642H-transplanted mice was not possible due to expansion of residual CD8+ T cells (Fig. S1E, F), which forced us to terminate the experiment. However, after 4 weeks, increased numbers of NK cells were also detected in the spleen upon transplantation of CD3-depleted hSTAT5BN642H compared to hSTAT5B BM (Fig. S1G).
To investigate long-term effects of hSTAT5BN642H on innate lymphocytes, we sorted Lineage (Lin)− (CD3/B220/Ter119/Gr1/CD11b) Sca1−c-Kit−CD127−CD8− cells. This cellular fraction is devoid of hematopoietic stem cells, common lymphoid progenitors, and CD8+ T cells and was obtained from hSTAT5BN642H or hSTAT5B BM for further transplantation into Rag2−/−γc−/− recipient mice. We monitored NK and T cell numbers in the blood over a period of 5 weeks. Again, a modest increase but subsequent drop in NK cell numbers in mice transplanted with hSTAT5BN642H compared to hSTAT5B BM cells was observed (Fig. S1H), whereas we failed to detect CD8+ T cells in the blood of the recipient animals (Fig. S1I). This indicated that our sorting strategy successfully eliminated CD8+ T cell disease, but did not allow us to uncover persistent hSTAT5BN642H-mediated NK cell expansion. Of note, after 4.5–10 months all three hSTAT5BN642H-recipient mice (#1–3) developed a rapidly progressing disease, characterized by expansion of CD3+NK1.1+ NKT cells in blood, BM, spleen, and liver (Fig. 1c, Table S1). Disease development was restricted to transplantation of mutant hSTAT5B cells and was not detected upon transplantation of hSTAT5B BM, despite following up these animals for 10 months.
To investigate, whether hSTAT5BN642H NKT cells are indeed transformed and fulfill the criteria of being leukemic, we started to perform serial whole BM transplants from the earlier diseased recipient #1 (survival: 133 d) with the presumably more aggressive disease. To do so, we transplanted BM containing 1 × 106 NKT cells into immune-deficient Rag2−/−γc−/− or NSG-recipient mice. This serial transplantation approach was continued for a total of six rounds. The first two rounds were performed to maintain and amplify the NKT cell disease. We confirmed the presence of the hSTAT5BN642H transgene in a diseased mouse (Fig. S1J). Upon the 3rd to the 6th round of serial transplant, we characterized the manifested disease as an aggressive leukemia accompanied by hepatosplenomegaly (Fig. 2a), increased white blood cell (WBC) counts (Fig. S2A) and a high frequency of NKT cells in blood, BM, spleen, and liver (Fig. S2C, D) with a mean survival of 17.6 days (Fig. S2B). Infiltration of leukemic cells into various organs was confirmed by histological analysis (Fig. S2E). In the 6th round, a titration of transplanted NKT cell numbers was performed. Disease severity at the end point was comparable, while a delay of 3 days occurred between each titration step (Fig. 2a, Fig. S2A–D). Despite the increased disease latency in recipients #2 (survival: 294 d) and #3 (survival: 301 d), the disease could also be serially transplanted giving rise to a similarly aggressive disease (Fig. S3A–H) as for recipient #1.
A more detailed characterization of surface markers on transformed NKT cells from the serially transplanted disease of recipient #1 verified expression of the T cell receptor (TCR) β chain, while CD4, CD8, and TCRγδ expression was not detected. Leukemic cells also stained positive for CD122 and the NK cell markers NKp46 and DX5. No interaction with the CD1d tetramer was observed (Fig. 2b). This surface marker profile corresponds to previously described CD1d-independent NKT cells [8, 9], which were recently identified as a source for CD3+NK1.1+ T-cell large granular lymphocyte (T-LGL) leukemia in IL-15 transgenic mice [10]. In analogy to our NKT cell leukemia model, human CD56+ T-LGL leukemia cells were also shown to express NKp46 [10]. Additionally, CD3+CD56+ blasts in human T-LGL leukemia express CD8 [4]. Interestingly, we found CD8 expressed on a subset of hSTAT5BN642H NKT leukemia cells in the two later diseased recipients #2 and #3, but not in recipient #1 (Table S1).
Furthermore, the serially transplanted leukemic NKT cells from recipient #1 were largely negative for activating and inhibitory NK cell receptors, except for Ly49G2 and KLRG1 (Fig. S4A), but stained positive for CD43, CD44, and CD69, while lacking CD62L (Fig. S4A). In summary, this surface receptor expression profile is consistent with an activated phenotype comparable to the leukemic blasts found in IL-15 transgenic mice [11]. The fact that IL-15 transgenic mice develop NK1.1+ T-LGL (NKT) or NK cell leukemia [10, 11] supports the importance of the IL-15-STAT5 axis for the transformation of subsets of innate lymphocytes. The occurrence of leukemia with an NKT cell profile in our model suggests that additional IL-15-derived signals, independent of STAT5, may be required for NK cell transformation. In contrast to IL-15 transgenic mice, in which transformation is restricted to innate-like lymphocytes, NKp46+ NKT cell disease required the absence of classical CD8+ T cells bearing mutant hSTAT5B in vivo. As NKp46+ NKT cells represent a minor population [10], the higher number of CD8+ T cells may simply outcompete potentially transformed NKT cells. Alternatively, it is possible that CD8+ T cells actively suppress the development of NKT cell tumors providing a hostile tumor microenvironment.
hSTAT5BN642H-driven CD8+ T cell disease is susceptible to JAK1/JAK2 inhibition by Ruxolitinib treatment [7]. As JAK inhibitors have also been suggested as therapeutic strategy for NK/T-cell lymphoma and aggressive NK cell leukemia [6, 12], we transplanted NSG mice with hSTAT5BN642H NKT leukemia cells and treated them with ruxolitinib for 3 weeks. Treatment attenuated disease severity and decreased hepatosplenomegaly and WBC counts compared to the control group (Fig. 2c and Fig. S4B).
Although initial attempts to grow transformed NKT cells in vitro failed, after 6–8 weeks we detected outgrowth of hSTAT5BN642H NKT cell lines from cultured hepatic leukocytes of three out of nine NSG mice from different serial transplant rounds from recipient #1 (Table S2, Fig. S5A). Two cell lines, derived from the same mouse cultured without or with IL-2 (4165_1 and 4165_2, respectively), were treated with Ruxolitinib and remained sensitivity towards it (IC50 of 83 and 72.5 nM, respectively) (Fig. S5B). Furthermore, these cell lines could give rise to leukemia when injected into immune-competent Ly5.1/CD45.1+ mice (Fig. S5C–E).
In this study, we identify STAT5BN642H as an oncogenic driver in innate-like lymphocytes. Our novel NKT leukemia model, which is serially transplantable and inducible by frozen material or from cell lines, recapitulates human CD56+ LGL leukemia and provides new means for translational research. It will allow a deeper understanding of mechanisms driving NKT leukemia progression and maintenance as well as facilitate finding new therapeutic options. This is of vital importance as the STAT5BN642H mutation in CD56+ LGL leukemia patients is associated with a particularly aggressive chemo-refractory phenotype [4].
References
Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood. 2011;117:1565–74.
Gotthardt D, Sexl V. STATs in NK-cells: the good, the bad, and the ugly. Front Immunol. 2017;7:1–8.
Villarino AV, Sciumè G, Davis FP, Iwata S, Zitti B, Robinson GW, et al. Subset- and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells. J Exp Med. 2017;214:2999–3014.
Rajala HLM, Eldfors S, Kuusanm H, Van Adrichem AJ, Olson T, Lagstr S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121:4541–51.
Küçük C, Jiang B, Hu X, Zhang W, Chan JKC, Xiao W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun. 2015;6:6025.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018;9:1–12.
Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, et al. STAT5B N642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018;128:387–401.
Maeda M, Shadeo A, Macfadyen AM, Takei F. CD1d-independent NKT cells in β 2 -microglobulin-deficient mice have hybrid phenotype and function of NK and T cells. J Immunol. 2004;172:6115–22.
Farr AR, Wu W, Choi B, Cavalcoli JD, Laouar Y. CD1d-unrestricted NKT cells are endowed with a hybrid function far superior than that of iNKT cells. Proc Natl Acad Sci USA. 2014;111:12841–6.
Yu J, Tridandapani S, Caligiuri MA, Yu J, Mitsui T, Wei M, et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest. 2011;121:1456–70.
Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, et al. A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. Leuk Res. 2010;34:1–14.
Hee YT, Yan J, Nizetic D, Chng W. LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). Oncotarget. 2018;9:31832–41.
Acknowledgments
We thank Sabine Fajmann and Philipp Jodl for great technical support and Manuela Kindl for maintaining and monitoring the mice.
Funding
The work was supported by the Austrian Science Fund FWF grant SFB-F06105 to RM and SFB-F06107 to VS and FWF grant W1212 to VS.
Author information
Authors and Affiliations
Contributions
VS initiated and supervised the study. KK, AWS, and BM designed the experiments; KK, AWS, BM, DP, and NL performed the experiments; MPM and TS provided technical support; KK and GH analyzed the data; RM provided the mouse model. KK and VS wrote the manuscript. AWS, BM, DP, TS, and RM revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Klein, K., Witalisz-Siepracka, A., Maurer, B. et al. STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. Leukemia 33, 2336–2340 (2019). https://doi.org/10.1038/s41375-019-0471-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0471-3